利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.031 秒)

    COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION
    1.
    发明申请
    COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION 审中-公开
    化学和方法来衡量代谢功能和恢复正常代谢功能

    公开(公告)号：US20110274689A1

    公开(公告)日：2011-11-10

    申请号：US13100895

    申请日：2011-05-04

    申请人： Kenneth Walsh ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Noriyuki Ouchi

    IPC分类号： A61K38/16 ,  G01N33/53 ,  C12Q1/68 ,  G01N33/566 ,  A61K39/395 ,  A61P3/08

    摘要： The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor.

    摘要翻译： 本发明涉及恢复正常代谢功能的治疗，包括但不限于正常的葡萄糖水平。 在一个实施方案中，本发明考虑了通过施用包含至少一部分人Sfrp5的组合来降低具有升高的葡萄糖水平的受试者的升高的葡萄糖水平的方法。 在一个实施方案中，本发明考虑了通过施用包含但不限于抗体抑制剂的Wnt5a抑制剂的组合物降低葡萄糖水平升高的受试者中升高的葡萄糖水平的方法。

    METABOLIC AND CARDIOPROTECTION BY THE MYOKINE FOLLISTATIN-LIKE 1 POLYPEPTIDE
    5.
    发明申请
    METABOLIC AND CARDIOPROTECTION BY THE MYOKINE FOLLISTATIN-LIKE 1 POLYPEPTIDE 有权
    由MYOKINE FOLLISTATIN-LIKE 1 POLYPEPTIDE代谢和保护

    公开(公告)号：US20100227817A1

    公开(公告)日：2010-09-09

    申请号：US12682898

    申请日：2008-10-20

    申请人： Kenneth Walsh ,  Yuichi Oshima ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Yuichi Oshima ,  Noriyuki Ouchi

    IPC分类号： A61K38/22 ,  A61P9/10 ,  A61P3/08

    CPC分类号： A61K38/1709 ,  Y10S514/824 ,  Y10S514/866

    摘要： Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.

    摘要翻译： 本文描述了与发现Follistatin样1蛋白（Fst1-1）在体内具有代谢和心脏保护作用有关的方法和组合物。 Fstl-1及其部分和衍生物或变体可用于治疗或预防代谢疾病或病症，并治疗或预防心脏肌肉供血中断引起的心脏损伤。

    Method
    6.
    发明申请
    Method 审中-公开
    方法

    公开(公告)号：US20080057521A1

    公开(公告)日：2008-03-06

    申请号：US11765745

    申请日：2007-06-20

    申请人： Martin Barnardo ,  Andrea Harmer ,  Michael Bunce ,  Robert Vaughn ,  Kenneth Walsh

    发明人： Martin Barnardo ,  Andrea Harmer ,  Michael Bunce ,  Robert Vaughn ,  Kenneth Walsh

    IPC分类号： G01N33/00

    CPC分类号： G01N33/6854 ,  G01N33/543 ,  G01N33/566 ,  Y10S435/975

    摘要： The invention provides a method of detecting the presence of anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and detecting the binding or absence of binding of antibodies to said recombinant MHC molecules. This method allows the detection and/or identification of one or more specific MHC particularly HLA allele antibodies

    摘要翻译： 本发明提供了一种检测样品中抗MHC抗体的存在的方法，包括使所述样品与一种或多种重组MHC分子或功能等同的变体，衍生物或片段接触并检测抗体与所述重组体的结合或结合 MHC分子。 该方法允许检测和/或鉴定一种或多种特异性MHC，特别是HLA等位基因抗体

    Beverage lid dispenser
    7.
    发明申请
    Beverage lid dispenser 有权

    公开(公告)号：US20060249526A1

    公开(公告)日：2006-11-09

    申请号：US11121373

    申请日：2005-05-04

    申请人： Kenneth Walsh ,  Nicholas Walsh

    发明人： Kenneth Walsh ,  Nicholas Walsh

    IPC分类号： B65G59/00

    CPC分类号： G07F11/045 ,  A47F1/106 ,  B65G59/105 ,  G07F13/10

    摘要： The current invention is a lid dispensing device and method of use comprising a base unit, a lid holder operatively connected to the base unit, a blade operatively mounted to the base which moves between a first position and a second position, the blade supporting a stack of lids by engaging a first lid in the stack of lids while the blade is in the first position, and the blade allowing the first lid to fall through an aperture in the blade away from the stack of lids, and still support the remaining stack of lids as the blade moves to the second position.

    Growth arrest homeobox gene
    8.
    发明申请
    Growth arrest homeobox gene 审中-公开

    公开(公告)号：US20060141476A1

    公开(公告)日：2006-06-29

    申请号：US10784513

    申请日：2004-02-23

    申请人： David Gorski ,  Kenneth Walsh

    发明人： David Gorski ,  Kenneth Walsh

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C12N9/99

    CPC分类号： C07K14/4703 ,  A61K38/00

    摘要： A novel growth arrest homeobox gene has been discovered and the nucleotide sequences have been determined in both the rat and the human. The expression of the novel homeobox gene inhibits vascular smooth muscle cell growth. The growth arrest homeobox gene hereinafter referred to as the “Gax gene” and its corresponding proteins are useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty.

    Compounds and Methods to Measure Metabolic Function and Restore Normal Metabolic Function
    10.
    发明申请
    Compounds and Methods to Measure Metabolic Function and Restore Normal Metabolic Function 审中-公开

    公开(公告)号：US20190292256A1

    公开(公告)日：2019-09-26

    申请号：US16259150

    申请日：2019-01-28

    申请人： Kenneth Walsh ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Noriyuki Ouchi

    IPC分类号： C07K16/28 ,  C07K16/18 ,  A61K38/17

    摘要： The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor.